GLYCTK

Across TCGA pan-cancer cohorts, GLYCTK mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLYCTK data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLYCTK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GLYCTK expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where GLYCTK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.964	0.821	.002	26	view →
UCEC	DFS	Median	III,IV	0.464	1.000	.010	22	view →
PDAC	OS	Quartile	II,III,IV	0.832	0.267	.020	20	view →
LUAD	OS	Median	All	0.392	0.883	.007	11	view →
LSCC	DFS	Tertile	All	1.000	0.612	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLYCTK–CCRCC (OS)

Open the CCRCC breakdown →